Escitalopram in Schizophrenia in OCD- Open Label Study

This study has been completed.
Sponsor:
Collaborator:
Lundbeck Israel
Information provided by:
BeerYaakov Mental Health Center
ClinicalTrials.gov Identifier:
NCT00456937
First received: December 3, 2006
Last updated: January 26, 2009
Last verified: January 2009
  Purpose

SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology


Condition Intervention Phase
Schizophrenia
Drug: Escitalopram
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study

Resource links provided by NLM:


Further study details as provided by BeerYaakov Mental Health Center:

Estimated Enrollment: 15
Study Start Date: July 2006
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who suffer from schizophrenia and OCD

Exclusion Criteria:

  • Substance abuse,
  • Serious medical condintions,
  • Being on SSRI treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00456937

Locations
Israel
Beer Yaakov MHC
Beer Yaakov, Israel, 70350
Sponsors and Collaborators
BeerYaakov Mental Health Center
Lundbeck Israel
Investigators
Principal Investigator: Rafael Octavio Stryjer, M.D. Beer Yaakov Mental Health Center
  More Information

No publications provided

Responsible Party: Dr Rafael Stryjer, Beer-Yaakov MHC
ClinicalTrials.gov Identifier: NCT00456937     History of Changes
Other Study ID Numbers: Escitalopram-173CTIL
Study First Received: December 3, 2006
Last Updated: January 26, 2009
Health Authority: United States: Food and Drug Administration
Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Obsessive-Compulsive Disorder
Schizophrenia
Anxiety Disorders
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Dexetimide
Citalopram
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Serotonin Agents

ClinicalTrials.gov processed this record on July 23, 2014